Mufg Securities Americas Inc. Acquires 27,314 Shares of Pfizer Inc. $PFE

Mufg Securities Americas Inc. grew its holdings in Pfizer Inc. (NYSE:PFE) by 21.7% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 153,318 shares of the biopharmaceutical company’s stock after buying an additional 27,314 shares during the quarter. Mufg Securities Americas Inc.’s holdings in Pfizer were worth $3,907,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. Peak Asset Management LLC boosted its stake in Pfizer by 1.4% in the 2nd quarter. Peak Asset Management LLC now owns 28,768 shares of the biopharmaceutical company’s stock valued at $697,000 after buying an additional 402 shares in the last quarter. Community Bank & Trust Waco Texas grew its holdings in Pfizer by 0.6% during the 3rd quarter. Community Bank & Trust Waco Texas now owns 66,841 shares of the biopharmaceutical company’s stock worth $1,703,000 after acquiring an additional 412 shares during the last quarter. Able Wealth Management LLC increased its holdings in shares of Pfizer by 2.0% in the second quarter. Able Wealth Management LLC now owns 21,128 shares of the biopharmaceutical company’s stock valued at $512,000 after purchasing an additional 413 shares in the last quarter. CVA Family Office LLC increased its stake in shares of Pfizer by 3.3% in the 3rd quarter. CVA Family Office LLC now owns 12,915 shares of the biopharmaceutical company’s stock valued at $329,000 after buying an additional 413 shares during the period. Finally, Boltwood Capital Management increased its position in Pfizer by 0.7% in the third quarter. Boltwood Capital Management now owns 58,274 shares of the biopharmaceutical company’s stock worth $1,485,000 after purchasing an additional 420 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Price Performance

Pfizer stock opened at $27.04 on Tuesday. The company has a market capitalization of $153.71 billion, a price-to-earnings ratio of 19.88 and a beta of 0.47. The company has a current ratio of 1.28, a quick ratio of 0.97 and a debt-to-equity ratio of 0.62. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $27.94. The stock’s 50 day moving average is $25.96 and its 200-day moving average is $25.34.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.09. The firm had revenue of $17.56 billion for the quarter, compared to analysts’ expectations of $16.93 billion. Pfizer had a return on equity of 20.25% and a net margin of 12.42%.The company’s quarterly revenue was down 1.2% compared to the same quarter last year. During the same quarter last year, the business earned $0.63 EPS. Equities research analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, January 23rd. This represents a $1.72 dividend on an annualized basis and a yield of 6.4%. Pfizer’s payout ratio is currently 126.47%.

Analyst Upgrades and Downgrades

Several analysts have commented on PFE shares. Scotiabank began coverage on shares of Pfizer in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $30.00 target price for the company. Zacks Research downgraded shares of Pfizer from a “hold” rating to a “strong sell” rating in a report on Monday, January 26th. Cantor Fitzgerald restated a “neutral” rating and issued a $27.00 price target on shares of Pfizer in a report on Wednesday, February 4th. Daiwa Securities Group lowered shares of Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price objective on the stock. in a research report on Thursday, February 12th. Finally, Guggenheim reissued a “buy” rating on shares of Pfizer in a research report on Wednesday, December 17th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, thirteen have issued a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $27.84.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Erste Group raised its earnings estimates for Pfizer, which supports higher forward earnings expectations and helps justify current valuations. Erste Group Bank Increases Earnings Estimates for Pfizer
• Positive Sentiment: Telescope Innovations announced installation of a second Self-Driving Laboratory at Pfizer — a signal that Pfizer is investing in automated R&D platforms that could accelerate drug discovery efficiency (small direct revenue impact but positive for long-term R&D productivity). Telescope Innovations Installs Second Self-Driving Lab at Pfizer
• Positive Sentiment: Pfizer appears on dividend-focused stock lists (e.g., The Motley Fool), which can boost demand from income-oriented investors. My 5 Favorite Dividend Stocks to Buy Right Now
• Neutral Sentiment: Pfizer invited the public to listen to CEO Albert Bourla’s presentation at the TD Cowen Health Care Conference on March 2 — an event that could move the stock if management provides new guidance or program updates. Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
• Neutral Sentiment: Coverage pieces (Zacks / Yahoo) note heightened investor attention on PFE; these articles can increase trading interest but don’t by themselves change fundamentals. Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
• Neutral Sentiment: Neutrolis appointed former Pfizer R&D chief Mikael Dolsten to its board — notable industry movement but not a direct driver for Pfizer’s near-term results. Neutrolis Appoints Mikael Dolsten, M.D., Ph.D., to Board of Directors as Executive Director

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.